Biosimilars and Biologics in Cancer Treatment

Nyhet

An Era in Therapeutic Strategies

Häftad, Engelska, 2026

Av Kuttiappan Anitha, Shvetank Bhatt, Nagaraju Bandaru

2 189 kr

Kommande

Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses challenges and opportunities in biosimilars and biologics, integrating the latest evidence, regulatory landscapes, economic implications, and strategies to enhance cancer management. The book aims to create an all-inclusive educational resource, bridge the gap between research and clinical practice, and inspire future research in oncology. It provides a comprehensive examination of cancer therapeutics, starting with an introduction to biologics and biosimilars, their historical development, and foundational principles. Sections explain mechanisms of action, drug development processes, regulatory landscapes, and clinical applications through case studies.

Emerging therapeutic strategies, including combination therapies and personalized medicine, are also covered. This book benefits researchers, oncologists, pharmacologists, pathologists, and other healthcare professionals by offering up-to-date insights into the clinical aspects of biological medications and their biosimilars. Contributions from global experts ensure readers gain the latest advancements and practical guidance on integrating these therapies into clinical practice and research.

Provides an in-depth analysis of biologics and biosimilars, covering their historical development, mechanisms of action, drug development processes, and regulatory landscapes
Includes case studies and practical examples that highlight the use of biologics and biosimilars in cancer treatment, showcasing their efficacy, safety profiles, and emerging therapeutic strategies such as combination therapies and personalized medicine
Offers diverse and comprehensive perspectives, ensuring readers gain insights into the latest advancements and future directions in biosimilars and biologics, along with practical guidance for integrating these therapies into clinical practice and research

Produktinformation

Utgivningsdatum2026-06-01
Mått191 x 235 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor440
FörlagElsevier Science
ISBN9780443438240

Tillhör följande kategorier

Biologi inom Naturvetenskap och teknik

Dr. Kuttiappan Anitha is working as Assistant Professor in School of Pharmacy and Technology Management (SPTM), SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Shirpur. She has broad teaching and research experience. Dr. Anitha is recipient of “Excellence in Academic Award 2022 from International School of Technology and Sciences Affiliated from Govt. of India. She has guided more than 45 M.Pharm students and more than 10 batches of UG Projects. She has more than 30 publications in both national and international journals. Her area of expertise includes Immunooncology, endocrine areas, Gut Microbiota, infectious Diseases. She has also written several books and many book chapters. She has organized Conferences/seminars at university levels.Dr. Shvetank Bhatt is an accomplished Associate Professor in the School of Health Sciences and Technology at Dr. Vishwanath Karad MIT World Peace University, located in Pune, Maharashtra, India. He holds an M. Pharm degree in Pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka, and a Ph.D. in Neuropharmacology from Birla Institute of Technology & Science (BITS) Pilani, Pilani Campus, Rajasthan. With many years of industrial and academic research experience, Dr. Bhatt specializes in CNS disorders, pain, inflammation, and immuno-oncology. He has received numerous accolades, including the Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award for Best Paper in Pharmacology-IJPER in 2012 and 2014. Dr. Bhatt has published dozens of papers in various national and international journals. Dr. Bhatt is a life member of the Association of Pharmaceutical Teachers of India (APTI) and the Indian Pharmacological Society (IPS).Nagarau Bandaru completed his B. Pharm (2011) and M. Pharm (2013) in Pharmacology from Shri Vishnu College of Pharmacy, Bhimavaram, and earned his PhD (2021) from Acharya Nagarjuna University, Guntur, AP, India. With 10 years of teaching experience, he has published 48 research and review papers, 6 patents, and 8 books. He has presented at numerous national and international seminars and conferences and delivered guest lectures at various Indian universities. His accolades include the Best Teacher award from K L University, Best Researcher, Young Scientist, and Distinguished Alumni awards from Shri Vishnu College of Pharmacy. He has received fellowships such as GPAT AICTE and CSIR NEIST summer research fellowship. His research focuses on Neuropharmacology. He has guided many M. Pharm and B. Pharm student projects and is an approved Ph.D. supervisor at Sandip University and K L University. He has also completed 4 NGO projects and secured funded grants.

1. Introduction to Biosimilars and Biologics2. Opportunities and Challenges in the Biosimilars and Biologics3. Impact of Biosimilars and Biologics in Cancer Treatment4. Clinical Applications of Biologics and Biosimilars in Oncology5. Biosimilars and Biologics in Breast Cancer6. Biosimilars and Biologics in Gastric and Colorectal Cancer7. Biosimilars and Biologics in Cervical Cancer8. Biosimilars and Biologics in Lung Cancer9. Biosimilars and Biologics in Hepatocellular Carcinoma10. Biosimilars and Biologics in Brain Tumor11. Biosimilars and Biologics in Pancreatic Cancer12. Biosimilars and Biologics in Prostate Cancer13. Biosimilars and Biologics in Ovarian Cancer14. Biosimilars and Biologics in Bone Cancer15. Biosimilars and Biologics in Endometrial/Uterine Cancer16. Biosimilars and Biologics in Urothelial Carcinoma17. Biosimilars and Biologics in Melanoma18. Biologics and Biosimilars from the Bench to the Bedside in Oncology19. Recent Evidence of Biologics and Biosimilars and its Perspectives on Clinical Advances and Emerging Approaches20. Marching of Biologics and Biosimilars in Artificial Intelligence and Machine Learning as Tools to Detect Various Cancer